Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/1098960]Researchers: A/Pr Michele Teng (Principal investigator) , Prof Mark Smyth (Principal investigator)
Brief description There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.
Funding Amount $AUD 760,148.29
Funding Scheme Project Grants
Notes Standard Project Grant
- nhmrc : 1098960
- PURL : https://purl.org/au-research/grants/nhmrc/1098960